With Prasad Back at FDA, Capricor To Fight CRL for DMD Cardiomyopathy
Capricor Therapeutics met with the FDA last week for a type A meeting, during which CEO Linda Marbán aimed to explain to the regulator that it got it wrong. Capricor plans to resubmit the application based on deramiocel’s existing dataset.Read more:
biospace.comBiotechnology